Monkeypox Virus: A Comprehensive Overview of Viral Pathology, Immune Response, and Antiviral Strategies.

immune responses monkeypox virus (mpox) outbreak poxviruses therapeutics vaccines

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
09 Aug 2023
Historique:
received: 19 06 2023
revised: 22 07 2023
accepted: 26 07 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

The years 2022-2023 witnessed a monkeypox virus (mpox) outbreak in some countries worldwide, where it exists in an endemic form. However, the number of infectious cases is continuously on the rise, and there has been an unexpected, drastic increase in cases that result from sustained transmission in non-endemic regions of the world. Under this scenario, it is pertinent for the world to be aware of healthcare threats to mpox infection. This review aimed to compile advanced data regarding the different aspects of mpox disease. A comprehensive strategy for the compilation of recent data was adopted to add data regarding mpox, biology, viral pathology, immune response, and brief details on the antiviral strategies under trial; the search was limited to 2016-2023. The aim is to make the scientific community aware of diverse aspects of mpox. Consequently, detailed insights have been drawn with regard to the nature, epidemiology, etiology, and biological nature of mpox. Additionally, its host interaction and viral infectious cycle and immune interventions have been briefly elaborated. This comprehensively drawn literature review delivers brief insights into the biological nature, immune responses, and clinical developments in the form of therapeutics against mpox. This study will help scientists understand the biological nature and responses in hosts, which will further help clinicians with therapeutic handling, diagnosis, and treatment options. This study will provide updated information on mpox's pathology, immune responses, and antiviral strategies. Moreover, it will also help the public to become educated on the healthcare-associated threat and take timely mitigation measures against expected mpox outbreaks in the future.

Sections du résumé

BACKGROUND BACKGROUND
The years 2022-2023 witnessed a monkeypox virus (mpox) outbreak in some countries worldwide, where it exists in an endemic form. However, the number of infectious cases is continuously on the rise, and there has been an unexpected, drastic increase in cases that result from sustained transmission in non-endemic regions of the world. Under this scenario, it is pertinent for the world to be aware of healthcare threats to mpox infection. This review aimed to compile advanced data regarding the different aspects of mpox disease.
METHODS METHODS
A comprehensive strategy for the compilation of recent data was adopted to add data regarding mpox, biology, viral pathology, immune response, and brief details on the antiviral strategies under trial; the search was limited to 2016-2023. The aim is to make the scientific community aware of diverse aspects of mpox.
RESULTS RESULTS
Consequently, detailed insights have been drawn with regard to the nature, epidemiology, etiology, and biological nature of mpox. Additionally, its host interaction and viral infectious cycle and immune interventions have been briefly elaborated. This comprehensively drawn literature review delivers brief insights into the biological nature, immune responses, and clinical developments in the form of therapeutics against mpox. This study will help scientists understand the biological nature and responses in hosts, which will further help clinicians with therapeutic handling, diagnosis, and treatment options.
CONCLUSIONS CONCLUSIONS
This study will provide updated information on mpox's pathology, immune responses, and antiviral strategies. Moreover, it will also help the public to become educated on the healthcare-associated threat and take timely mitigation measures against expected mpox outbreaks in the future.

Identifiants

pubmed: 37631913
pii: vaccines11081345
doi: 10.3390/vaccines11081345
pmc: PMC10459537
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

N Engl J Med. 2023 Jun 29;388(26):2434-2443
pubmed: 37199451
J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e368-e371
pubmed: 36166329
N Engl J Med. 2022 Aug 18;387(7):579-581
pubmed: 35921403
Ann Med Surg (Lond). 2022 Aug;80:104197
pubmed: 35855873
J Eur Acad Dermatol Venereol. 2023 Jun 16;:
pubmed: 37328930
Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5991-6003
pubmed: 36066177
Travel Med Infect Dis. 2022 Nov-Dec;50:102481
pubmed: 36265732
Ther Adv Infect Dis. 2022 Nov 14;9:20499361221136751
pubmed: 36406813
Indian Pediatr. 2022 Aug 15;59(8):636-642
pubmed: 35762024
MMWR Morb Mortal Wkly Rep. 2022 Oct 07;71(40):1278-1282
pubmed: 36201401
Virol Sin. 2022 Aug;37(4):477-482
pubmed: 35820590
Front Microbiol. 2023 May 05;14:1160984
pubmed: 37213509
Future Virol. 2013 Feb 1;8(2):129-157
pubmed: 23626656
Viruses. 2022 Dec 29;15(1):
pubmed: 36680142
N Engl J Med. 2022 Aug 25;387(8):679-691
pubmed: 35866746
Viruses. 2020 Nov 05;12(11):
pubmed: 33167496
Expert Rev Vaccines. 2018 Oct;17(10):925-934
pubmed: 30300041
Indian J Virol. 2013 Dec;24(3):295-305
pubmed: 24426291
J Med Virol. 2023 Jan;95(1):e28036
pubmed: 35906185
Microb Pathog. 2022 Dec;173(Pt A):105794
pubmed: 36179973
Front Immunol. 2020 Aug 28;11:1637
pubmed: 32983084
ACS Infect Dis. 2016 Nov 11;2(11):787-799
pubmed: 27933782
Open Forum Infect Dis. 2022 Jun 23;9(7):ofac310
pubmed: 35891689
Emerg Microbes Infect. 2022 Dec;11(1):1768-1777
pubmed: 35751396
Int J Infect Dis. 2023 Apr;129:175-180
pubmed: 36740013
Antiviral Res. 2021 Nov;195:105179
pubmed: 34530009
Viruses. 2022 Sep 03;14(9):
pubmed: 36146766
Int J Vet Sci Med. 2022 Feb 28;10(1):11-18
pubmed: 35291581
J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e412-e414
pubmed: 36152029
Emerg Infect Dis. 2022 Oct;28(10):2123-2125
pubmed: 35960545
Nat Rev Immunol. 2022 Oct;22(10):597-613
pubmed: 36064780
Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300
pubmed: 25896687
Nat Med. 2023 Jan;29(1):270-278
pubmed: 36257333
Front Public Health. 2023 Jan 24;11:1052946
pubmed: 36761122
Cell Host Microbe. 2022 Dec 14;30(12):1662-1670.e4
pubmed: 36463861
PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141
pubmed: 35148313
Travel Med Infect Dis. 2022 Nov-Dec;50:102447
pubmed: 36067937
Int Immunopharmacol. 2022 Dec;113(Pt A):109364
pubmed: 36283221
J Am Acad Dermatol. 2022 Nov;87(5):1069-1074
pubmed: 35817333
Int J Surg. 2022 Sep;105:106869
pubmed: 36049620
Lancet Child Adolesc Health. 2022 Nov;6(11):751-753
pubmed: 35926522
Viruses. 2022 Aug 27;14(9):
pubmed: 36146705
mSphere. 2021 Feb 3;6(1):
pubmed: 33536322
Travel Med Infect Dis. 2022 Nov-Dec;50:102448
pubmed: 36087645
J Virol. 2015 Oct;89(20):10489-99
pubmed: 26246580
Viruses. 2023 Mar 02;15(3):
pubmed: 36992376
J Virol. 2017 Sep 12;91(19):
pubmed: 28747505
Adv Virus Res. 2017;97:187-243
pubmed: 28057259
Am J Trop Med Hyg. 2015 Aug;93(2):410-5
pubmed: 26013374
Eur J Intern Med. 2023 Jan;107:108-109
pubmed: 36270934
Int J Mol Sci. 2022 Jul 17;23(14):
pubmed: 35887214

Auteurs

Shiza Malik (S)

Bridging Health Foundation, Rawalpindi 46000, Pakistan.

Amna Ahmed (A)

Department of Oncology, Jinnah Hospital, Lahore 54550, Pakistan.

Omar Ahsan (O)

Department of Medicine, Foundation University Medical College, Foundation University Islamabad, Islamabad 44000, Pakistan.

Khalid Muhammad (K)

Department of Biology, College of Sciences, UAE University, Al Ain 15551, United Arab Emirates.

Yasir Waheed (Y)

Office of Research, Innovation, and Commercialization (ORIC), Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), Islamabad 44000, Pakistan.
Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon.

Classifications MeSH